Pipeline
Our lead candidate RN-077 (and back-up compound RN-081) is a small molecule therapy exiting the Discovery Phase, that targets both amyloid-β and tau pathologies, which offers a rare opportunity to modify Alzheimer's Disease at its roots, not just manage symptoms. It does this by inhibiting a key kinase implicated in multiple disease mechanisms and demonstrated to ameliorate learning and memory deficits in animal models.
Key Features of RN-077
Our partner (and licensor)’s drug discovery program has produced a clinical candidate with a highly desirable profile for treating chronic neurological disease:
Proven Target Engagement: In-vivo studies have confirmed that oral administration of RN-077 inhibits tau phosphorylation in a dose-dependent manner, providing clear proof-of-mechanism.
First-in-Class Potential: RN-077 targets a novel kinase for which there are currently no approved drugs, positioning it as a potential first-in-class intervention.
Excellent Drug-like Properties: RN-077 is a small molecule with high potency and excellent penetration of the blood-brain barrier. It is designed for oral, once-a-day administration, making it suitable for chronic use and potentially more cost-effective than biologic therapies
